208 related articles for article (PubMed ID: 2997349)
21. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
22. [The sensitivity and specificity of tumor markers (CEA, ferritin, beta 2-MG, TPA, IAP, sialic acid) in malignant and non-malignant pulmonary diseases and their relation to smoking and sex].
Reshad K; Suzuki K; Inui K; Takahashi Y; Umemiya M; Nakano Y; Sakamoto M; Takeuchi Y; Shimada T
Nihon Kyobu Shikkan Gakkai Zasshi; 1985 Nov; 23(11):1343-50. PubMed ID: 3912573
[No Abstract] [Full Text] [Related]
23. Evaluation of CA125 as a circulating tumor marker for ovarian cancer.
Kuzuya K; Nozaki M; Chihara T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):949-57. PubMed ID: 3461071
[TBL] [Abstract][Full Text] [Related]
24. Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sekiya S; Takamizawa H; Suzuki N; Tokita H
Arch Gynecol Obstet; 1988; 243(2):69-81. PubMed ID: 3165255
[TBL] [Abstract][Full Text] [Related]
25. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
[TBL] [Abstract][Full Text] [Related]
26. [Auxiliary value of TPA in diagnosing neoplastic diseases].
Mizushima Y; Nakamura F; Yokoyama A; Morikage T; Kawasaki S; Hoshino K; Maruyama M; Yamashita N; Yano S
Gan No Rinsho; 1986 Jun; 32(7):779-82. PubMed ID: 3735675
[TBL] [Abstract][Full Text] [Related]
27. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
28. [Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma].
Iwasaka T; Ohkuma Y; Yoshimura T; Sugimori H
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):917-23. PubMed ID: 2426378
[TBL] [Abstract][Full Text] [Related]
29. [Tumor-associated markers in malignant lung neoplasms].
Piancino G; Racca P; Rayneri W; Piantino P; Cerchier A; Pecchio F
Minerva Med; 1986 Jan; 77(1-2):19-25. PubMed ID: 3945411
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significances of tissue polypeptide antigen in patients with gynecological malignancies].
Ueda M; Sudo N; Furuya M; Arakawa O; Ikarashi T
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Nov; 37(11):2361-8. PubMed ID: 3001201
[TBL] [Abstract][Full Text] [Related]
31. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors].
Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374
[TBL] [Abstract][Full Text] [Related]
33. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer].
Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H
Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042
[TBL] [Abstract][Full Text] [Related]
34. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
35. [A study on tumor marker of tissue-polypeptide-antigen (TPA) in gynecologic malignancies].
Nakajima H; Hirata T; Norisugi T; Furuno K; Ikehata N; Utsunomiya A; Kobayashi K; Negishi Y; Akiya K
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Oct; 36(10):1877-83. PubMed ID: 6094688
[TBL] [Abstract][Full Text] [Related]
36. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
[TBL] [Abstract][Full Text] [Related]
37. [The values of urine cysteine protein activity in the diagnosis of ovarian cancer].
Xi MR; Peng ZL; Cao ZY
Zhonghua Fu Chan Ke Za Zhi; 1994 Feb; 29(2):85-7, 123. PubMed ID: 8033632
[TBL] [Abstract][Full Text] [Related]
38. [Diagnosis of ovarian tumor by measuring tumor markers].
Fukatsu T; Nakashima N; Takeuchi J
Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
[TBL] [Abstract][Full Text] [Related]
39. [Changes in serum levels of gynecological tumor markers throughout the period from early gestation to puerperium].
Sugawara T; Tanaka T; Sato H; Hanatani K; Okuyama K; Shinkai N; Sakuragi N; Makinoda S; Fujimoto S
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Feb; 43(2):145-51. PubMed ID: 1707431
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of different serum tumor markers in gynecological malignancies.
Paulick R; Caffier H; Horner G; Lang K; Filbry E
Cancer Detect Prev; 1985; 8(1-2):115-20. PubMed ID: 4064031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
